Biosimilar User Fee Negotiations Won't Start Until 2016
Executive Summary
Mid-December kick-off meeting puts emerging user fee program on much later track than others.
You may also be interested in...
Biosimilar User Fee Talks Reach Starting Line As Report Shows Growing FDA Workload
Agency staff efforts dedicated to 351(k) reviews increased more than 10-fold in fiscal year 2015, Eastern Research Group says.
Biosimilar Market Formation Isn't Going According To Plan
As user fee negotiations begin, FDA has far more sponsors in product development phase and far fewer marketing applications than anticipated.
Biosimilar User Fees Could Be Raised Significantly In Renewal Talks
Workload is not what was expected when BsUFA was designed, FDA says.